Table 5.

Changes in JKOM total score (items II–V) and normal walking speed at each time point in subjects with mild-to-severe knee pain and baseline K–L grade ≥II or ≤I^a

Variables	K–L grades ≥II				K–L grades ≤ I
	JKOM total score (points)		Normal walking speed (m/s)		JKOM total score (points)		Normal walking speed (m/s)
Values at each time pointb	GCQID	Placebo	GCQID	Placebo	GCQID	Placebo	GCQID	Placebo
Baseline	29.7±14.8	13.7±2.6	1.16±0.07	1.28±0.04	15.8±1.8	15.7±1.5	1.27±0.04	1.25±0.04
Week 4	24.3±14.9	12.0±3.4			12.9±2.0	14.3±2.0
Week 8	9.3±2.4	14.2±3.8	1.31±0.13	1.30±0.05	10.5±1.7	13.1±1.8	1.33±0.05	1.28±0.04
Week 12	9.3±1.5	13.0±5.3			10.9±2.3	11.9±1.6
Week 16	8.0±2.6	9.3±2.8	1.35±0.08	1.35±0.06*	9.4±1.9*	11.0±1.4	1.37±0.04**	1.28±0.04
Two-way ANOVA (group × time) P-value	0.082		0.064		0.634		0.193

Notes:

^aGCQID group (n=3), placebo group (n=6) for K–L grade ≥II. GCQID group (n=20), placebo group (n=19) for K–L grade ≤I.

^bValues expressed as mean ± standard error.

^*P<0.05 and

^**P<0.01 compared with baseline values.

Abbreviations: ANOVA, analysis of variance; GCQID, glucosamine hydrochloride, chondroitin sulfate, type II collagen peptides, quercetin glycosides, imidazole peptides, and vitamin D; JKOM, Japanese Knee Osteoarthritis Measure; K–L, Kellgren–Lawrence.